Panakeia

Panakeia is a London-based medtech company developing an AI platform that profiles cancer biomarkers directly from routine H&E-stained pathology images, eliminating the need for separate molecular tests. The thesis: most cancer patients today receive a diagnosis only after multiple tissue tests run in sequence, taking weeks or months — a delay that materially affects treatment outcomes.

The company's PANProfiler product applies deep learning to digital pathology slides to predict the status of multiple biomarkers — genetic, transcriptomic, proteomic and metabolomic — within minutes of a single H&E sample. PANProfiler Breast (HER2 Negative) is UKCA-marked, and the company runs early-access programmes with hospitals while building the clinical evidence base for further regulatory submissions.

Founded in 2018 by Pahini Pandya and Pandu Raharja-Liu, Panakeia has raised approximately $3.8M in seed funding from six investors and employs around a dozen specialists across oncology, machine learning and software engineering. The company has been selected for Tech Nation's Applied AI 2.0, Creative Destruction Lab, King's 20 and InnovateUK programmes.